01 The global neurorehabilitation devices market is primarily boosted by the surging prevalence of neurological illnesses like migraine, dementia, Alzheimer's disease, brain tumors, epilepsy, and others worldwide. Moreover, the demand for innovative and effective technologies is expected to increase in tandem with the growing population's need for neurorehabilitation treatments, leading to the introduction of new products in the market and thereby creating opportunities for market expansion.Neurorehabilitation devices refer to medical equipment specifically designed to assist in the rehabilitation and recovery of individuals affected by neurological illnesses or traumas. These devices are employed to enhance or reinstate the operational capabilities of the neurological system, encompassing the brain, spinal cord, and peripheral nerves. Neurological illnesses and traumas can lead to various impairments, including abnormalities in motor function, sensory perception, and cognitive abilities.Neurorehabilitation devices can address multiple facets of rehabilitation and are frequently utilized with additional therapeutic approaches. The primary objective of neurorehabilitation devices is to optimize overall well-being and promote self-sufficiency among those afflicted with neurological disorders. These gadgets are frequently employed as components of a comprehensive rehabilitation regimen customized to cater to each person's unique requirements.
June 2026 NeuroLife launched as a commercial neurotechnology company through a strategic partnership between Battelle and The NeuroTech Institute, alongside a USD 2.9 million seed funding round to accelerate development and commercialization of its wearable neurorehabilitation platform for stroke and spinal cord injury recovery.
May 2026 MindMaze Therapeutics and Vibra Healthcare signed a definitive channel partnership agreement to expand deployment of MindMaze’s FDA-cleared digital neurorehabilitation platform across leading U.S. health systems, strengthening access to advanced neurorehabilitation technologies.
April 2026 Bioness Medical acquired the PoNS (Portable Neuromodulation Stimulator) System, expanding its neurorehabilitation portfolio with non-invasive central neuromodulation technology for patients with gait and balance disorders resulting from neurological conditions.
July 2025 Sunrise Medical completed the acquisition of Made for Movement, expanding its neurorehabilitation portfolio with motor-assisted standing, robotic gait training, and therapeutic mobility devices for patients with stroke, cerebral palsy, spinal cord injury, and other neurological disorders.